MacroGenics Inc
MGNX1.645USD
+0.065+4.11%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
103.78MCap. mercado
PérdidaP/E TTM
Más Datos de MacroGenics Inc Compañía
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Información de la empresa
Símbolo de cotizaciónMGNX
Nombre de la empresaMacroGenics Inc
Fecha de salida a bolsaOct 10, 2013
Director ejecutivoDr. Scott Koenig, M.D., Ph.D.
Número de empleados341
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 10
Dirección9704 Medical Center Drive
CiudadROCKVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20850
Teléfono13012515172
Sitio Webhttps://www.macrogenics.com/
Símbolo de cotizaciónMGNX
Fecha de salida a bolsaOct 10, 2013
Director ejecutivoDr. Scott Koenig, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Scott Koenig, M.D., Ph.D.
Dr. Scott Koenig, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.37M
+45.23%
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
11.00K
+144.44%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
Chief Operating Officer
Chief Operating Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Scott Koenig, M.D., Ph.D.
Dr. Scott Koenig, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.37M
+45.23%
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
11.00K
+144.44%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 9 de jul
Actualizado: mié., 9 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bellevue Asset Management AG
15.74%
Armistice Capital LLC
9.98%
BlackRock Institutional Trust Company, N.A.
7.13%
The Vanguard Group, Inc.
7.02%
Wasatch Global Investors Inc
5.15%
Other
54.98%
Accionistas
Accionistas
Proporción
Bellevue Asset Management AG
15.74%
Armistice Capital LLC
9.98%
BlackRock Institutional Trust Company, N.A.
7.13%
The Vanguard Group, Inc.
7.02%
Wasatch Global Investors Inc
5.15%
Other
54.98%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
35.01%
Investment Advisor/Hedge Fund
21.21%
Hedge Fund
20.14%
Private Equity
5.03%
Individual Investor
3.10%
Research Firm
2.87%
Pension Fund
0.53%
Bank and Trust
0.10%
Family Office
0.02%
Other
12.00%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
350
55.50M
87.97%
-21.64M
2025Q1
365
56.04M
88.82%
-21.64M
2024Q4
367
57.72M
91.98%
-20.16M
2024Q3
367
57.51M
91.64%
-21.39M
2024Q2
370
63.01M
100.47%
-16.59M
2024Q1
368
67.02M
107.12%
-8.36M
2023Q4
353
64.08M
103.25%
-12.72M
2023Q3
352
60.31M
97.24%
-15.19M
2023Q2
356
62.23M
100.48%
-18.91M
2023Q1
389
60.87M
98.46%
-22.53M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bellevue Asset Management AG
9.93M
15.74%
--
--
Jun 01, 2025
Armistice Capital LLC
6.30M
9.98%
+20.00K
+0.32%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
7.13%
-147.34K
-3.17%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
7.02%
+109.31K
+2.53%
Mar 31, 2025
Wasatch Global Investors Inc
3.25M
5.15%
-238.25K
-6.83%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.18M
5.03%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.31M
3.66%
+1.02M
+78.84%
Mar 31, 2025
Millennium Management LLC
1.72M
2.73%
-1.14M
-39.81%
Mar 31, 2025
Two Sigma Investments, LP
1.72M
2.73%
-256.25K
-12.95%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.46M
2.31%
+22.97K
+1.60%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Vanguard US Momentum Factor ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
SPDR S&P Biotech ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%
Invesco Nasdaq Biotechnology ETF
Proporción0.01%
Vanguard US Momentum Factor ETF
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
SPDR S&P Biotech ETF
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
iShares Genomics Immunology and Healthcare ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
